Auditor Issues Going Concern Warning Amidst Widening Losses and Leadership Changes

summarizeSummary

NervGen Pharma Corp. received a 'going concern' warning from its auditor, reporting a significant increase in net losses and a need for further financing, despite positive clinical trial updates for its lead drug candidate.

check_boxKey Events

• Auditor's Going Concern Warning

  The independent auditor's report explicitly states a 'material uncertainty' regarding the company's ability to continue as a going concern for the next 12 months, citing the need for additional financing or cost reductions.

• Significant Increase in Net Loss

  The company reported a net loss of $44.1 million for the year ended December 31, 2025, a substantial increase from $24.3 million in 2024, contributing to an accumulated deficit of $146.8 million.

• Recent Capital Raises and Program Termination

  NervGen completed a non-brokered private placement in November 2025, raising US$10.0 million (CAD$14.1 million), and terminated its At-The-Market (ATM) equity program in March 2026 after raising CAD$2.7 million through it. Subsequent to year-end, an additional $1.9 million from stock option exercises and $0.8 million from warrant exercises were received.

• Positive Clinical Trial Progress

  The company announced positive topline results and expanded clinical findings from the chronic cohort of its Phase 1b/2a CONNECT SCI Study for NVG-291, with preparations underway for a Phase 3 clinical trial in chronic spinal cord injury. The subacute cohort is ongoing.

auto_awesomeAnalysis

NervGen Pharma Corp.'s auditor has issued a 'going concern' warning, indicating a material uncertainty about the company's ability to continue operations for the next 12 months. This critical financial risk is highlighted by a significant increase in net loss to $44.1 million in 2025 from $24.3 million in 2024. Despite recent capital raises, including a $14.1 million private placement in November 2025 and $2.7 million from an At-The-Market (ATM) program (which was subsequently terminated), the company's cash burn rate and accumulated deficit of $146.8 million raise serious concerns about its financial viability. The stock is currently trading near its 52-week low, reflecting investor apprehension. While the company reported positive topline clinical data for its lead drug candidate, NVG-291, in chronic spinal cord injury and is preparing for a Phase 3 trial, the financial challenges pose a substantial hurdle to its development plans. Investors should closely monitor the company's ability to secure additional financing and manage its operating costs to address the going concern risk.